Contec Medical Systems Co (300869) Fair Value & Analysis
Healthcare · CN · Market cap 4.4B CNY
Analysis
Contec Medical Systems Co (300869) currently trades at ¥11.53, while our model-based Fair Value estimate is ¥19.41 — implying the stock looks roughly 68.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Contec Medical Systems Co.,Ltd engages in the research and development, production, and sale of medical diagnosis and monitoring equipment in China and internationally. The company offers electronic sphygmomanometers, ambulatory blood pressure monitors, pulse oximeters, patient monitors, stethoscopes, simulators, multi-parameter vital signs monitors, central monitoring systems, electrocardiograph products, endoscopes, pocket fetal dopplers, fetal monitors, ultrasound diagnostic systems, analyzers, infusion pumps, digital brain electric activity mapping and EMG/EP systems, nebulizers, spirometers, oxygen concentrators, capnographs, and airway pressure devices. It also provides infusion and syringe pumps, massagers, sleep and snoring aids, and thermometers; and telemedicine and veterinary products, dispensing appliances, electronic colposcope, and accessories. In addition, the company engages in the import and export, trade, related consulting, and customer service of medical equipmen…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.